SCHEMBL2365683

SCHEMBL2365683

CCC1COC(=O)N1c1ccc(C(=O)N2CCN(c3ncc(C4CC4)cc3C)CC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 3/20 0.38
P2RX2 Q9UBL9 3/20 0.38
EGLN1 Q9GZT9 1/20 0.37
CXCR3 P49682 4/20 0.37
SLC6A7 Q99884 1/20 0.36
KMT2A Q03164 5/20 0.36
VNN1 O95497 1/20 0.36
GAA P10253 1/20 0.36
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PKM P14618 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365671 1.00 P2RX3 (0.38) P2RX3P2RX2EGLN1CXCR3SLC6A7
SCHEMBL2366914 0.94 EGLN1 (0.38) P2RX3P2RX2EGLN1SLC6A7KMT2A
SCHEMBL2366911 0.94 EGLN1 (0.38) P2RX3P2RX2EGLN1SLC6A7KMT2A
SCHEMBL2365943 0.92 P2RX3 (0.37) P2RX3P2RX2EGLN1CXCR3SLC6A7
SCHEMBL2365950 0.92 P2RX3 (0.37) P2RX3P2RX2EGLN1CXCR3SLC6A7
SCHEMBL2366652 0.91 LMNA (0.39) EGLN1SLC6A7KMT2AGAAALDH1A1
SCHEMBL2366647 0.91 LMNA (0.39) EGLN1SLC6A7KMT2AGAAALDH1A1
SCHEMBL12240526 0.90 FASN (0.39) P2RX3P2RX2EGLN1CXCR3KMT2A
SCHEMBL2366574 0.90 P2RX3 (0.44) P2RX3P2RX2CXCR3KMT2AGAA
SCHEMBL2366568 0.90 P2RX3 (0.44) P2RX3P2RX2CXCR3KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 P2RX3 3992/4885P2RX2 3651/4885EGLN1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.